Fluoroquinolones and anaerobes.

Area of Science:

• Microbiology
• Infectious Diseases
• Pharmacology

Background:

• Fluoroquinolones are increasingly evaluated for treating mixed aerobic and anaerobic infections.
• Newer fluoroquinolone compounds exhibit enhanced in vitro activity against anaerobic bacteria.
• Clinically relevant susceptibility breakpoints for anaerobic bacteria remain unestablished.

Purpose of the Study:

• To investigate the utility of fluoroquinolones in treating mixed aerobic and anaerobic infections.
• To assess the role of newer fluoroquinolone agents against anaerobic pathogens.
• To review current knowledge on fluoroquinolone use for anaerobic infections.

Main Methods:

• Review of in vitro activity data for newer fluoroquinolones against anaerobic bacteria.
• Analysis of pharmacodynamic properties of fluoroquinolones.
• Evaluation of data from recent clinical trials on fluoroquinolone efficacy.
• Assessment of resistance trends in key anaerobic pathogens, such as the Bacteroides group.

Main Results:

• Newer fluoroquinolones demonstrate improved in vitro activity against anaerobic organisms.
• Pharmacodynamic analyses and clinical trial data support potential use in specific infections.
• Effective treatment of skin/soft-tissue, intra-abdominal, and respiratory mixed infections is suggested.
• Increasing resistance in Bacteroides isolates and risk of Clostridium difficile-associated disease are noted concerns.

Conclusions:

• Newer fluoroquinolones may be valuable for treating certain mixed aerobic and anaerobic infections.
• Further research is needed to establish susceptibility breakpoints for anaerobic bacteria.
• Monitoring antimicrobial resistance and potential side effects is crucial for expanding fluoroquinolone use.